A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
There are new TB vaccines already developed that need to be tried in humans to assess their
efficacy.
The researchers had previously shown that production of interferon gamma by T cells in
response to TB antigens is a more specific marker of TB infection.
The researchers hypothesize that this can be used as a reliable early marker of TB vaccine
efficacy. The researchers expect to show a significantly increased reversion of this test in
household contacts of TB patients given Isoniazid prophylaxis treatment for 6 months.